We greatly appreciate Dr. Stummer’s and Dr. Thomas’s interest in our study and their important comments [1]. Due to their pioneering work in the field of the application of 5-aminolevulinic acid (5-ALA) in brain tumor surgery [2,3,4], it is a special honor that we added “an important contribution to the field” according to the authors’ opinion.
We congratulate Jaber et al. [5] on conducting the first systematical single center study in a large patient cohort and again pioneering work in this field investigating the prognostic value of 5-ALA in World Health Organization (WHO) grade II gliomas. As stated in our manuscript [6] and the comment, we performed “the first study […] in two specialized independent centers”. As also stated in our manuscript, “We were able to confirm […] the findings of the recent study conducted by Jaber et al.” [5]. Therefore, the results of our current independent study conducted at two specialized centers confirm and thus highlight the importance of visible intraoperative 5-ALA fluorescence as a prognostic factor in pure WHO grade II gliomas as first shown in the single center study by Jaber et al. [5].
We also thank the authors for the effort of summarizing and comparing the results of both studies [5,6]. Indeed, the number of isocitrate dehydrogenase (IDH) wildtype low-grade gliomas (LGG) was lower in our cohort (n = 5) compared to the study of Jaber et al. [5]. However, the exact number of IDH wildtype LGG included in this study by Jaber et al. is not fully clear for us. According to Table 1 of your comment, 46 IDH mutated gliomas were included; i.e., 28 IDH wildtype gliomas should be expected in this cohort accordingly. Interestingly, according to the Results section, including Table 2 of the original publication of Jaber et al. [5], only 16 IDH wildtype gliomas were indicated. Nevertheless, a higher portion of IDH wildtype gliomas were analyzed in the study by Jaber et al. [5] compared to our study [6]. Due to the low number of IDH wildtype gliomas in our cohort (n = 5), the statistical power of a multivariate survival analysis was thus too low. Since we were not able to perform a multivariate analysis, we cannot compare our results based on univariate analysis with the findings of the multivariate analysis of Jaber et al. [5], which identified IDH mutational status and fluorescence as independent prognostic factors for survival. Ideally, future studies including multiple centers with a high number of IDH wildtype LGG would be desirable to finally clarify the precise relationship between 5-ALA fluorescence and molecular markers in LGG, such as IDH status.
We fully agree with the authors of the comment that visible intraoperative 5-ALA fluorescence is an unfavorable prognostic factor in pure LGG according to the data of both studies, and thus we also agree with the comment that early initiation of radio- and chemotherapy should be considered in these patients.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Stummer, W.; Thomas, C. Comment on Hosmann et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)—Experience at Two Specialized Centers. Cancers 2021, 13, 2540. Cancers 2021, 13, 5634. [Google Scholar] [CrossRef]
- Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.-J. ALA-Glioma Study Group Fluorescence-Guided Surgery with 5-Aminolevulinic Acid for Resection of Malignant Glioma: A Randomised Controlled Multicentre Phase III Trial. Lancet Oncol. 2006, 7, 392–401. [Google Scholar] [CrossRef]
- Stummer, W.; Stocker, S.; Wagner, S.; Stepp, H.; Fritsch, C.; Goetz, C.; Goetz, A.E.; Kiefmann, R.; Reulen, H.J. Intraoperative Detection of Malignant Gliomas by 5-Aminolevulinic Acid-Induced Porphyrin Fluorescence. Neurosurgery 1998, 42, 518–525. [Google Scholar] [CrossRef] [PubMed]
- Stummer, W.; Novotny, A.; Stepp, H.; Goetz, C.; Bise, K.; Reulen, H.J. Fluorescence-Guided Resection of Glioblastoma Multiforme by Using 5-Aminolevulinic Acid-Induced Porphyrins: A Prospective Study in 52 Consecutive Patients. J. Neurosurg. 2000, 93, 1003–1013. [Google Scholar] [CrossRef] [PubMed]
- Jaber, M.; Ewelt, C.; Wölfer, J.; Brokinkel, B.; Thomas, C.; Hasselblatt, M.; Grauer, O.; Stummer, W. Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas? Neurosurgery 2018, 84, 1214–1224. [Google Scholar] [CrossRef]
- Hosmann, A.; Millesi, M.; Wadiura, L.I.; Kiesel, B.; Mercea, P.A.; Mischkulnig, M.; Borkovec, M.; Furtner, J.; Roetzer, T.; Wolfsberger, S.; et al. 5-ALA Fluorescence Is a Powerful Prognostic Marker during Surgery of Low-Grade Gliomas (WHO Grade II)-Experience at Two Specialized Centers. Cancers 2021, 13, 2540. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).